Stem Cell Therapies Face Long Road to Market Despite Decades of Promise

(서울=뉴스1) 김정은 기자 = Stem cell therapies have long been hailed as a potential breakthrough in medicine, offering the possibility of regenerating damaged tissue and treating diseases that conventional therapies cannot fully address. Interest in the field remains strong, with clinical trials underway for conditions including Parkinson’s disease, Alzheimer’s disease, liver cirrhosis and spinal cord injuries.

Yet despite the promise, relatively few stem cell therapies have achieved commercial success. While development timelines are not necessarily longer than those of traditional drugs, the hurdles to commercialization are often significantly higher.

South Korea’s first stem cell therapy took nine years to reach approval

One notable example is Hearticellgram-AMI, South Korea’s first approved stem cell therapy. The treatment, which uses mesenchymal stem cells derived from a patient's own bone marrow to treat acute myocardial infarction, received regulatory approval in 2011.

What stands out is how much longer development took than initially expected. Early projections suggested commercialization could be achieved within three to four years, but the process ultimately took about nine years. Researchers and developers had to navigate not only scientific and clinical challenges, but also business operations, fundraising and regulatory requirements.

The development effort also coincided with a period of heightened public skepticism toward stem cell research, creating additional difficulties. Some patients reportedly considered withdrawing from clinical trials amid growing concerns surrounding the field.

As a result, industry observers say the commercialization of Hearticellgram-AMI demonstrated that the greatest challenge was not necessarily technological innovation itself, but sustaining long-term clinical development and regulatory efforts through years of uncertainty.

Manufacturing and quality control remain major barriers

Even after safety and efficacy are demonstrated in clinical trials, commercialization is far from guaranteed.

Unlike conventional pharmaceuticals, which can be manufactured repeatedly using standardized chemical ingredients, stem cell therapies rely on living cells as the therapeutic product. As a result, product characteristics can vary depending on cell conditions, culture environments and manufacturing processes.

Developers must prove they can consistently produce cells with the same quality and therapeutic properties, while also demonstrating that manufacturing changes do not alter efficacy or safety. Securing reliable cell sources, maintaining rigorous quality-control systems, conducting long-term safety assessments and establishing cold-storage and distribution networks are all critical requirements.

Regulators have placed increasing emphasis on these issues. The U.S. Food and Drug Administration, for example, treats chemistry, manufacturing and controls (CMC) as a central component of reviews for cell and gene therapies.

Commercialization also requires substantial financial resources. Industry estimates suggest that developing innovative therapies for global markets can require investments ranging from hundreds of millions of dollars to more than $700 million. While overall development costs for stem cell therapies are broadly comparable to those of traditional drug programs, additional investments are often needed to establish cell-production capabilities and quality-control systems.

Commercialization expected to expand gradually in targeted indications

Despite the challenges, companies continue investing in stem cell therapies because of their long-term market potential.

Aging populations are driving increases in chronic and degenerative diseases such as dementia, Parkinson’s disease, liver cirrhosis and osteoarthritis, while treatment options that address the underlying causes of these conditions remain limited.

If stem cell therapies can successfully regenerate damaged tissues or slow disease progression, they could create entirely new treatment categories beyond those served by conventional medicines.

Orthopedic conditions, including cartilage defects and osteoarthritis, are widely viewed as among the most commercially viable applications. In South Korea, stem cell therapies for knee cartilage defects have already received regulatory approval and are being used clinically.

Other promising areas include immune-mediated and inflammatory diseases, graft-versus-host disease (GVHD), and rare or difficult-to-treat conditions.

Liver cirrhosis is also emerging as a potential commercialization target. Because treatment options remain limited outside of liver transplantation, stem cell therapies could offer a new therapeutic alternative. Several South Korean companies are currently conducting late-stage clinical trials for liver cirrhosis, Parkinson’s disease, spinal cord injuries and other indications.

Industry experts generally expect the stem cell therapy market to develop gradually rather than through a single transformative breakthrough. While some musculoskeletal and rare-disease applications have already reached patients, broader adoption is likely to occur indication by indication over the next five to 10 years.

“Stem cell therapies are a field where commercialization hurdles are often greater than the development timeline itself,” an industry official said. “The ability to secure high-quality source cells, maintain robust quality-control systems and navigate regulatory requirements across different markets will be key determinants of future competitiveness.”

1derland@news1.kr